昆仑文化
500-999人
公司优势
20,861+ 岗位更新等你来订阅
一键订阅最新的岗位，每周送达
🎉恭喜你，订阅成功
继续订阅您可以在邮箱中随时取消订阅
衡水卓宁鱼缸制品有限公司成立于2016年，位于河北省衡水市，是一家主要从事专业技术服务业的企业。
安徽众源新能源科技公司诚聘英才
哈尔滨云盛制冷设备销售有限公司成立于2023年5月25日，位于黑龙江省哈尔滨市南岗区王岗镇兴利村图号02-21-17地号1055，所属行业为其他机械设备及电子产品批发，员工规模1-49人，从事批发零售业务。
Visirna was founded in 2022 and has established a strategic partnership with Arrowhead Pharmaceuticals (NASDAQ: ARWR), a leading global company in small RNA drug development. The company currently has three clinical-stage siRNA drugs targeting cardiovascular and metabolic diseases. In addition, the company possesses independent R&D capabilities and is exploring liver-specific and extrahepatic delivery technologies, as well as broader therapeutic areas.
The company's current pipeline is at the forefront of its competitors, with targets supported by clear genomic and biological evidence, utilizing Arrowhead's validated delivery and chemical modification technology platforms. The company adopts a China-US collaborative clinical development and registration strategy to accelerate product commercialization.
The company's internal R&D capabilities will further enrich the clinical development pipeline in cardiovascular and metabolic diseases, promoting long-term sustainable development, while forming an integrated industry chain from R&D, production to sales through internal and external resources.
Visirna was founded in 2022 in a strategic partnership with Arrowhead Pharmaceuticals (NASDAQ: ARWR). Based in China, with a global vision, Visirna aims to be a leading player in the research and development of oligonucleotide therapeutics. We currently have three first-in-class late clinical-stage siRNA candidates licensed from Arrowhead Pharmaceuticals for the treatment of cardiovascular and metabolic diseases.
We are rapidly advancing our clinical pipelines in an array of trials. Currently we have one ongoing Phase 3 registration trial in FCS in China, and will soon join multiple MRCT trials for cardiovascular diseases. At the same time, we are also conducting a phase 2 PoC (proof of concept) trial in NASH.
Visirna is setting up a 1500 sqm R&D lab in Suzhou BioBAY to strengthen our existing clinical portfolio for cardiovascular and metabolic diseases. Our goal is to develop a comprehensive treatment repertoire that can effectively address the complex nature of these diseases and provide better outcomes for patients.
经营范围包括不干胶、医用双面胶带、保护膜制品的加工与销售及技术开发；塑料薄膜、绝缘材料、三色棉材料的加工与销售（以上危险品除外）；打印耗材及配件的加工与销售；五金标牌、包装盒、办公用品、金属制品、包装制品的销售。